国产紫杉醇联合化疗老年晚期非小细胞肺癌的临床观察  

作　　者：吕江清[1] 王云南[1] 邝浩斌[1] 黄冬生[1] 冯宝玲[1] 

机构地区：[1]广州市胸科医院肿瘤科,广东广州510095

出　　处：《中国现代应用药学》2005年第z3期877-878,共2页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的比较国产紫杉醇对老年和中青年晚期小细胞肺癌(NSCLC)的疗效和毒性,探讨老年患者化疗的可行性。方法将65例晚期非小细胞肺癌患者按中国年龄段划分标准分为老年组(年龄≥60岁)和中青年组(年龄<60岁),应用国产紫杉醇135~150mg/m^2,3h静脉滴注,卡铂300-350mg/m^2,静脉滴注,联合化疗,每4周为1周期,进行2~3周期。结果老年组和中青年组有效率分别为37.8%和39.2%,中位生存期为11.8个月和9.3个月,1年生存率分别为38.2%和31.4%,两组统计学分析无显著性(P>0.05)。主要毒性为骨髓抑制,白细胞减少,脱发,恶心、呕吐,关节、肌肉痛,老年组和中青年组统计学分析无显著性(P>0.05),均未见严重过敏反应。结论国产紫杉醇对一般状况尚好的老年晚期非小细胞肺癌患者同样有效.安全且耐受。OBJECTIVE To evaluate the activity and toxicity of domestic paclitaxel in elderly patients with advanced non-small cell lung cancer(NSCLC).METHODS Sixty-five patients with advanced NSCLC were divided into two groups;group A(age≥60)and group B(age <60).Domestic paclitaxel 135~150mg/m^2 were given intravenously in 3 hours,combined with carboplatin 300~350mg/m^2.It was repeated every four weeks,up to 2 to 3 cycles.RESULTS The response rate in group A was 37.8%,and that was 39.2%in group B.The median survival time in group A was 11.8 months,and that was 9.3 months in group B.The one-year survival rate in group A was 38.2%,and that was 31.4%group B.There was no significant difference between the two groups(P>0.05).The major toxicities included myelosuppression,neutropenia,alopecia,nausea,vomiting,arthralgia and muscle pain.There was no significant difference between the two groups(P>0.05).No severe anaphylaxis was observed in the two groups.CONCLUSION Domestic paclitaxel is an effective,safe and tolerable anti-tumor agent in the treatment of advanced NSCLC.

关 键 词：老年 紫杉醇 非小细胞肺癌 化疗 

分 类 号：R979.1[医药卫生—药品] R284[医药卫生—药学]